Publications by authors named "Kirushanthi Sakthithasan"
Article Synopsis
- - The study investigates the use of nitrosative/oxidative stress and metabolic biomarkers in exhaled breath condensate (EBC) to help diagnose chronic obstructive pulmonary disease (COPD), which is a major health issue affecting millions globally.
- - A cohort of 303 participants, mostly transit workers, underwent spirometry testing, with 7% being diagnosed with COPD, including mostly mild cases, highlighting difficulties in early detection.
- - Two specific biomarkers, Lactate and Malondialdehyde (MDA), showed promise in distinguishing COPD patients from non-COPD individuals with high accuracy, suggesting EBC testing could improve non-invasive COPD diagnostics in the future.
Exposure to ambient PM10 may increase the risk of chronic obstructive pulmonary disease (COPD) and lung function decline. We evaluated the long-term exposure to PM10 and its relationship with COPD prevalence and lung function in Parisian subway workers. Participants were randomly selected from a 15,000-subway worker cohort.
View Article and Find Full Text PDFIntroduction: Health effects after long-term exposure to subway particulate matter (PM) remain unknown due to the lack of individual PM exposure data. This study aimed to apply the job exposure matrix (JEM) approach to retrospectively assess occupational exposure to PM in the Parisian subway.
Methods: Job, the line and sector of the transport network, as well as calendar period were four JEM dimensions.
Background: We evaluated the efficacy of two antidotes, edetate calcium disodium (CaNaEDTA) and dimercaptosuccinic acid (DMSA), for the treatment of lead poisoning in adults.
Methods: Thirty-seven patients with blood lead concentrations >40 μg/dL and positive CaNaEDTA lead mobilization were randomized to receive 1050 mg/m/day of oral DMSA (n = 21) or 500 mg/m/day of intravenous CaNaEDTA (n = 16) over two five-day courses separated by a 10-day rest period. Efficacy of treatment was evaluated by blood lead assays on the first day of the two courses and 14 days after the end of treatment and baseline CaNaEDTA lead mobilization test and 14 days after the end of treatment.